{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:40:38Z","timestamp":1776069638038,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the Scientific and Technological Support Project of Guizhou Province","award":["Qian Ke He Zhi Cheng [2023] Yi Ban 262"],"award-info":[{"award-number":["Qian Ke He Zhi Cheng [2023] Yi Ban 262"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40268-026-00542-z","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:26:47Z","timestamp":1775194007000},"page":"117-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms"],"prefix":"10.1007","volume":"26","author":[{"given":"Hua","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songsong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"542_CR1","doi-asserted-by":"crossref","unstructured":"Van Harten M J, Remmers S, Van den Bergh R C N et al. Prostate cancer screening in Europe: future directions and perspectives. Prostate Cancer Prostatic Dis. 2025.","DOI":"10.1038\/s41391-025-00989-2"},{"key":"542_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17061013","author":"LC Ko","year":"2025","unstructured":"Ko LC, Gravina N, Berghausen J, et al. Rising trends in prostate cancer among Asian men: global concerns and diagnostic solutions. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17061013.","journal-title":"Cancers (Basel)"},{"key":"542_CR3","doi-asserted-by":"crossref","unstructured":"Goetzl E J, Washington S L. Recent advances in diagnosis and treatment of prostate cancer. Am J Med. 2025.","DOI":"10.1016\/j.amjmed.2025.06.002"},{"issue":"3","key":"542_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.semradonc.2025.05.003","volume":"35","author":"MK Rooney","year":"2025","unstructured":"Rooney MK, EL Kouzi Z, Kouzy R, et al. Debate 1: high-risk localized prostate cancer: why combination hormone therapy and radiotherapy is the optimal treatment strategy for most men. Semin Radiat Oncol. 2025;35(3):393\u2013401.","journal-title":"Semin Radiat Oncol"},{"issue":"12","key":"542_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jamaoncol.2016.3138","volume":"2","author":"L Klotz","year":"2016","unstructured":"Klotz L, Higano CS. Intermittent androgen deprivation therapy-an important treatment option for prostate cancer. JAMA Oncol. 2016;2(12):1531\u20132.","journal-title":"JAMA Oncol"},{"issue":"7","key":"542_CR6","first-page":"626","volume":"23","author":"ED Crawford","year":"2009","unstructured":"Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park). 2009;23(7):626\u201330.","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"542_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.urolonc.2022.10.018","volume":"41","author":"M Shiota","year":"2023","unstructured":"Shiota M, Endo S, Blas L, et al. Steroidogenesis in castration-resistant prostate cancer. Urol Oncol. 2023;41(5):240\u201351.","journal-title":"Urol Oncol"},{"issue":"3","key":"542_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, Mcmanus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354\u201373.","journal-title":"Endocr Rev"},{"issue":"11","key":"542_CR9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"542_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43561-5","volume":"13","author":"WS Shin","year":"2023","unstructured":"Shin WS, Han SH, Jo KW, et al. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer. Sci Rep. 2023;13(1):16663.","journal-title":"Sci Rep"},{"issue":"0","key":"542_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2021.07.013","volume":"519","author":"J Liang","year":"2021","unstructured":"Liang J, Wang L, Poluben L, et al. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. Cancer Lett. 2021;519(0):172\u201384.","journal-title":"Cancer Lett"},{"issue":"12","key":"542_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/iju.14366","volume":"27","author":"M Shiota","year":"2020","unstructured":"Shiota M, Machidori A, Abe T, et al. Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide. Int J Urol. 2020;27(12):1109\u201315.","journal-title":"Int J Urol"},{"issue":"1","key":"542_CR13","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/ERC-17-0355","volume":"25","author":"G Leone","year":"2018","unstructured":"Leone G, Tucci M, Buttigliero C, et al. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocr Relat Cancer. 2018;25(1):R1\u20139.","journal-title":"Endocr Relat Cancer"},{"issue":"0","key":"542_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.1053675","volume":"10","author":"Y Qi","year":"2022","unstructured":"Qi Y, Xue B, Chen S, et al. Synthesis, biological evaluation, and molecular docking of novel hydroxyzine derivatives as potential AR antagonists. Front Chem. 2022;10(0):1053675.","journal-title":"Front Chem"},{"key":"542_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2025.1557275","author":"H Jiang","year":"2025","unstructured":"Jiang H, Chen H, Wang Y, et al. Synthesis, bioactivity, and molecular docking studies: novel arylpiperazine derivatives as potential new-resistant AR antagonists. Front Chem. 2025. https:\/\/doi.org\/10.3389\/fchem.2025.1557275.","journal-title":"Front Chem"},{"key":"542_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.947065","author":"Q Yueheng","year":"2022","unstructured":"Yueheng Q, Hong C, Shijin C, et al. Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists. Front Chem. 2022. https:\/\/doi.org\/10.3389\/fchem.2022.947065.","journal-title":"Front Chem"},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"1557275","DOI":"10.3389\/fchem.2025.1557275","volume":"13","author":"H Jiang","year":"2025","unstructured":"Jiang H, Chen H, Wang Y, et al. Synthesis, bioactivity, and molecular docking studies: novel arylpiperazine derivatives as potential new-resistant AR antagonists. Front Chem. 2025;13:1557275.","journal-title":"Front Chem"},{"key":"542_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14267","author":"X Hongyan","year":"2019","unstructured":"Hongyan X, Cheng H, Shanshan B, et al. Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. J Cell Mol Med. 2019. https:\/\/doi.org\/10.1111\/jcmm.14267.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"542_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/aja202494","volume":"27","author":"RN Cole","year":"2025","unstructured":"Cole RN, Fang Q, Matsuoka K, et al. Androgen receptor inhibitors in treating prostate cancer. Asian J Androl. 2025;27(2):144\u201355.","journal-title":"Asian J Androl"},{"key":"542_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156464","volume":"139","author":"X Yuan","year":"2025","unstructured":"Yuan X, Yu S, Lin L, et al. Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K\/AKT and MAPK pathways. Phytomedicine. 2025;139:156464.","journal-title":"Phytomedicine"},{"issue":"0","key":"542_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175909","volume":"955","author":"S Rezaei","year":"2023","unstructured":"Rezaei S, Nikpanjeh N, Rezaee A, et al. PI3K\/Akt signaling in urological cancers: tumorigenesis function, therapeutic potential, and therapy response regulation. Eur J Pharmacol. 2023;955(0):175909.","journal-title":"Eur J Pharmacol"},{"issue":"Pt 2","key":"542_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116580","volume":"230","author":"C Xiubing","year":"2024","unstructured":"Xiubing C, Huazhen L, Xueyan W, et al. SERPINA1 promotes the invasion, metastasis, and proliferation of pancreatic ductal adenocarcinoma via the PI3K\/Akt\/NF-kappaB pathway. Biochem Pharmacol. 2024;230(Pt 2):116580.","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"542_CR23","doi-asserted-by":"publisher","first-page":"10081","DOI":"10.18632\/aging.204446","volume":"14","author":"Z Tang","year":"2022","unstructured":"Tang Z, Zhao P, Zhang W, et al. SALL4 activates PI3K\/AKT signaling pathway through targeting PTEN, thus facilitating migration, invasion and proliferation of hepatocellular carcinoma cells. Aging (Albany NY). 2022;14(24):10081\u201392.","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"542_CR24","doi-asserted-by":"publisher","first-page":"2410396","DOI":"10.1080\/0886022X.2024.2410396","volume":"46","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Huang H, Tao Y, et al. Sirt6 ameliorates high glucose-induced podocyte cytoskeleton remodeling via the PI3K\/AKT signaling pathway. Ren Fail. 2024;46(2):2410396.","journal-title":"Ren Fail"},{"issue":"5","key":"542_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"B Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"542_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575\u201386.","journal-title":"Cancer Cell"},{"issue":"17","key":"542_CR27","first-page":"4291","volume":"59","author":"ME McMenamin","year":"1999","unstructured":"McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59(17):4291\u20136.","journal-title":"Cancer Res"},{"issue":"20","key":"542_CR28","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","volume":"17","author":"TL Lotan","year":"2011","unstructured":"Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011;17(20):6563\u201373.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"542_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489\u2013501.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"542_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/tox.23943","volume":"39","author":"X Xu","year":"2024","unstructured":"Xu X, Xi N, Chen J, et al. Deoxynivalenol exposure induces oxidative stress and apoptosis in human keratinocytes via PI3K\/Akt and MAPK signaling pathway. Environ Toxicol. 2024;39(1):277\u201388.","journal-title":"Environ Toxicol"},{"key":"542_CR31","doi-asserted-by":"publisher","unstructured":"Hsieh Y Y, Lee K C, Cheng K C et al. Antrodin C isolated from Antrodia cinnamomea induced apoptosis through ROS\/AKT\/ERK\/P38 signaling pathway and epigenetic histone acetylation of TNFalpha in colorectal cancer cells. Antioxidants (Basel). 2023;12(3):764. https:\/\/doi.org\/10.3390\/antiox12030764.","DOI":"10.3390\/antiox12030764"},{"issue":"6","key":"542_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.eururo.2014.08.053","volume":"67","author":"RB Marques","year":"2015","unstructured":"Marques RB, Aghai A, de Ridder CMA, et al. High efficacy of combination therapy using PI3K\/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur Urol. 2015;67(6):1177\u201385.","journal-title":"Eur Urol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00542-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:40:50Z","timestamp":1776066050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-026-00542-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00542-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by the Scientific and Technological Support Project of Guizhou Province (Grant no. Qian Ke He Zhi Cheng [2023] Yi Ban 262).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study received approval from the Research Ethics Committee of the Zunyi Medical University (reference number: 2022ZH064).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not openly available owing to reasons of sensitivity and are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization, H.J.; methodology, M.Z.X.; software, S.S.J.; validation, H.J.; formal analysis, H.J.; investigation, W.Q.H.; resources, H.J.; data curation, W.Q.H.; writing\u2014original draft preparation, H.J.; writing\u2014review and editing, H.J.; funding acquisition, H.J. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}